Menstrually related migraine: Breaking the cycle in your clinical practice

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 52, Issue 10, 2007, Pages 888-895

  Silberstein, Stephen D ^a   Goldberg, Jay ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Migraine headache; Migraine with aura; Migraine without aura

Indexed keywords

ANALGESIC AGENT; MAGNESIUM; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; TRYPTAMINE DERIVATIVE;

FEMALE; HUMAN; MENSTRUAL CYCLE; MIGRAINE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MAGNESIUM; MENSTRUAL CYCLE; MIGRAINE DISORDERS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 38449119384     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Lipton RB, Diamond S, Reed M, et al: Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001;41:638-645
2. Bigal ME, Lipton RB, Stewart WF: The epidemiology and impact of migraine. Curr Neurol Neurosci Rep 2004;4:98-104
3. MacGregor EA, Hackshaw A: Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63: 351-353
4. Granella F, Sances G, Allais G, et al: Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707-716
5. Dowson AJ, Kilminster SG, Salt R, et al: Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: A general practice study. Headache 2005;45:274-282
6. Stang PE, Crown WH, Bizier R, et al: The family impact and costs of migraine. Am J Manag Care 2004;10:313-320
7. Hu XH, Markson LE, Lipton RB, et al: Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999;159:813-818
8. Silberstein SD: Migraine. Lancet 2004;363:381-391
9. Levy D, Jakubowski M, Burstein R: Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004;101:4274-4279
10. International Headache Society: The international classification of headache disorders. Second edition. Cephalalgia (suppl 1) 2004;24:1-151
11. Somerville BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972;22:355-365
12. Somerville BW: The role of progesterone in menstrual migraine. Neurology 1971;21:853-859
13. MacGregor EA: Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004;3:354-361
14. Massiou H, MacGregor EA: Evolution and treatment of migraine with oral contraceptives. Cephalalgia 2000;20:170-174
15. Heritage AS, Stumpf WE, Sar M, et al: Brainstem catecholamine neurons are target sites for sex steroid hormones. Science 1980;207:1377-1379
16. Dawson-Basoa MB, Gintzler AR: 17-β-Estradiol and progesterone modulate an intrinsic opioid analgesic system. Brain Res 1993;601:241-245
17. Hellström B, Lundberg U: Pain perception to the cold pressor test during the menstrual cycle in relation to estrogen levels and a comparison with men. Integr Physiol Behav Sci 2000;35:132-141
18. Puri V, Puri S, Svojanovsky SR, et al: Effects of oestrogen on trigeminal ganglia in culture: Implications for hormonal effects on migraine. Cephalagia 2006;26:33-42
19. Boyle CA: Management of menstrual migraine. Neurology 1999;53:S14-S18
20. Tzourio C, Kittner SJ, Bousser M-G, et al: Migraine and stroke in young women. Cephalalgia 2000;20:190-199
21. Etminan M, Takkouche B, Isorna FC, et al: Risk of ischaemic stroke in people with migraine: Systematic review and meta-analysis of observational studies (abstr). BMJ 2005;330:63
22. Kurth T, Slomke MA, Kase CS, et al: Migraine, headache, and the risk of stroke in women: A prospective study. Neurology 2005;64:1020-1026
23. Stang PE, Carson AP, Rose KM, et al: Headache, cerebrovascular symptoms, and stroke: The Atherosclerosis Risk in Communities Study. Neurology 2005;64:1573-1577
24. Donaghy M, Chang CL, Poulter N: Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry 2002;73:747-750
25. Lipton RB, Dodick D, Sadovsky R, et al: A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology 2003;61:375-382
26. Silberstein SD, Merriam GR: Estrogens, progestins, and headache. Neurology 1991;41:786-793
27. Allais G, Bussone G, De Lorenzo C, et al: Advanced strategies of short-term prophylaxis in menstrual migraine: State of the art and prospects. Neurol Sci (suppl 2) 2005;26:S125-S129
28. Matchar DB, Young WB, Rosenberg JH, et al: Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: http://www.aan.com/professionals/practice/pdfs/ gl0087.pdf. Accessed December 2, 2005
29. Food and Drug Administration: FDA announces important changes and additional warnings for COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective, non-steroidal anti-inflammatory drugs (NSAIDS). Available at: http://www.fda.gov/cder/drug/advisory/COX2.htm. Accessed December 2, 2005
30. Facchinetti F, Bonellie G, Kangasniemi P, et al: The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine: The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol 1995;86:911-916
31. Nett R, Landy S, Shackelford S, et al: Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-842
32. Loder E, Silberstein SD, Abu-Shakra S, et al: Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: A randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44:120-130
33. Silberstein SD, Massiou H, McCarroll KA, et al: Further evaluation of rizatriptan in menstrual migraine: Retrospective analysis of long-term data. Headache 2002;42:917-923
34. MacGregor EA, Keywood C: Frovatriptan is effective in menstrually associated migraine. Poster presented at Headache World 2000; London, September 3-7, 2000
35. Sances G, Martignoni E, Fioroni L, et al: Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study. Headache 1990;30:705-709
36. Facchinetti F, Sances G, Borella P, et al: Magnesium prophylaxis of menstrual migraine: Effects on intracellular magnesium. Headache 1991;31:298-301
37. Newman L, Mannix LK, Landy S, et al: Naratriptan as short-term prophylaxis of menstrually associated migraine: A randomized, double-blind, placebo-controlled study. Headache 2001;41:248-256
38. Silberstein SD, Elkind AH, Schreiber C, et al: A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-269
39. Géraud G, Keywood C, Senard JM: Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43: 376-388
40. de Lignieres B, Vincens M, Mauvais-Jarvis P, et al: Prevention of menstrual migraine by percutaneous oestradiol (abstr). Br Med J (Clin Res Ed) 1986;293:1540
41. Dennerstein L, Morse C, Burrows G, et al: Menstrual migraine: A double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988;2:113-120
42. Smite MG, van der Meer YG, Pfeil JP, et al: Perimenstrual migraine: Effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 1994;34:103-106
43. Pradalier A, Vincent D, Beaulieu PH, et al: Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In New Advances in Headache Research. Edited by RF Clifford. London, Smith-Gordon, 1994, pp 129-132
44. Aegidius K, Zwart JA, Hagen K, et al: Oral contraceptives and increased headache prevalence: The Head-HUNT Study. Neurology 2006;66:349-353
45. Mei D, Capuano A, Vollono C, et al: Topiramate in migraine prophylaxis: A randomised double-blind versus placebo study. Neurol Sci 2004;25:245-250
46. Diener HC, Tfelt-Hansen P, Dahlof C, et al: Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-950
47. Blau JN: Migraine pathogenesis: The neural hypothesis reexamined. J Neurol Neurosurg Psychiatry 1984;47:437-442